Preventing and Managing Cardiovascular Toxicities of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Cancer therapy & Oncology International Journal
doi 10.19080/ctoij.2018.10.555779
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Juniper Publishers

Related search

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2019English

Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal of Haematology
Hematology
2019English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy

Blood Cancer Journal
OncologyHematology
2012English

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Switches of Tyrosine-Kinase Inhibitors in Chronic Phase of Chronic Myeloid Leukemia in Real Life

American Journal of Hematology
Hematology
2018English

Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

International Journal of Clinical Pharmacology & Pharmacotherapy
2018English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation
2016English

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy